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AbstrAct
Objective this post hoc analysis of the phase iii 
active PSoriatic arthritis randomized trial (aStraea) 
evaluated the effect of baseline body mass index (BMi) on 
subsequent response to subcutaneous (Sc) abatacept in 
patients with psoriatic arthritis (Psa).
Methods in aStraea, patients with active Psa were 
randomised (1:1) to receive blinded weekly Sc abatacept 
125 mg or placebo for 24 weeks. treatment response 
at week 24 was assessed by the proportions of patients 
achieving american college of rheumatology 20% 
improvement response, Disease activity Score in 28 joints 
(DaS28 (c reactive protein (crP))) ≤3.6 and <2.6, Health 
assessment Questionnaire-Disability index reduction 
from baseline ≥0.35 and radiographic non-progression 
(defined as change from baseline ≤0 in Psa-modified total 
Sharp/van der Heijde score). responses were stratified by 
baseline BMi (underweight/normal, <25 kg/m2; overweight, 
25–30 kg/m2; obese, >30 kg/m2) and compared in 
univariate and multivariate models.
Results Of 212/213 and 210/211 patients with 
baseline BMi data in the abatacept and placebo groups, 
respectively, 15% and 19% were underweight/normal, 
36% and 27% were overweight, and 49% and 54% were 
obese. after adjusting for baseline characteristics, there 
were no significant differences for any outcome measure 
at week 24 with abatacept in the overweight or obese 
versus underweight/normal subgroup. in the placebo 
group, patients in the obese versus underweight/normal 
subgroup were significantly less likely to achieve DaS28 
(crP) <2.6 at week 24 (Or 0.26; 95% ci 0.08 to 0.87; 
p=0.03).
Conclusion BMi does not impact clinical or radiographic 
response to Sc abatacept in patients with Psa.
Trial registration number nct01860976.
InTROduCTIOn
Patients with psoriatic arthritis (PsA) are 
twice as likely as the general population to be 
obese, as defined by body mass index (BMI) 
≥30 kg/m2, with a prevalence of obesity 
among patients with PsA of 37%.1 Tumour 
necrosis factor inhibitors (TNFis), a class of 
biologic (b) disease-modifying antirheumatic 
drugs (DMARDs), are an effective treatment 
option for PsA; however, a meta-analysis of 20 
randomised clinical trials and 34 observational 
studies in patients with rheumatic diseases, 
including PsA, concluded that obesity is associ-
ated with reduced treatment response to TNFis 
in these patients.2 The effect of obesity on the 
efficacy of bDMARDs with other mechanisms 
of action is unclear. An understanding of the 
potential impact of BMI on treatment-related 
outcomes in PsA is important for informing 
clinical decision-making in practice; therefore, 
information on the effect of obesity on the effi-
cacy of non-TNFi bDMARDs for PsA is needed.
Key messages
What is already known about this subject?
 ► Patients with psoriatic arthritis (Psa) tend to have 
a higher body mass index (BMi) than the general 
population. a high BMi can be associated with less 
favourable clinical outcomes with biologics, such as 
tumour necrosis factor inhibitors.
What does this study add?
 ► this analysis evaluated the relationship between 
BMi and treatment response to subcutaneous (Sc) 
abatacept in patients with Psa.
 ► Obese and overweight patients with Psa had a sta-
tistically similar treatment response to Sc abatacept 
compared with patients who were underweight or 
had normal BMi.
How might this impact on clinical practice or 
future developments?
 ► these findings suggest that Sc abatacept could be 
considered for patients with Psa irrespective of BMi 
status.
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Abatacept is a cytotoxic T lymphocyte-associated anti-
gen-4-immunoglobulin fusion molecule that selectively 
modulates T-cell co-stimulation and activation through the 
inhibition of the CD80/CD86:CD28 co-stimulatory signal. 
T-cell-driven pathways are implicated in the pathogenesis of 
immunological diseases including PsA, making abatacept a 
plausible therapeutic candidate.3 Indeed, abatacept, avail-
able as an intravenous or subcutaneous (SC) formulation, 
is approved for the treatment of moderate-to-severe rheu-
matoid arthritis (RA), juvenile idiopathic arthritis and PsA.4 
Evidence from interventional trials and real-world studies 
has shown that BMI does not affect treatment response to 
abatacept in patients with RA.5 6 However, there are limited 
data on the impact of BMI on response to abatacept in 
patients with PsA.
In the randomised, double-blind, placebo-controlled, 
international phase III Active PSoriaTic Arthritis RAndom-
izEd TriAl (ASTRAEA), the American College of Rheu-
matology 20% improvement (ACR20) response rate in 
patients with PsA at week 24 was significantly higher with 
abatacept versus placebo.7 Here, we present findings from 
an analysis of ASTRAEA to explore the impact of patient 
BMI at baseline on the response to SC abatacept.
MeTHOds
study design and treatment
A post hoc analysis of the ASTRAEA study was conducted 
to evaluate the effect of baseline BMI on the response 
to SC abatacept in patients with PsA. The study design, 
ethics approvals, study population, patient eligibility 
criteria and main endpoints of ASTRAEA have been 
reported previously.7 The trial is registered at www. clin-
icaltrials. gov.
Briefly, patients with active PsA and an inadequate 
response or intolerance to ≥1 non-bDMARD were 
randomised (1:1) to receive blinded weekly SC abatacept 
125 mg or placebo for 24 weeks. Concomitant treatment 
with methotrexate, leflunomide, sulfasalazine or hydroxy-
chloroquine; non-steroidal anti-inflammatory drugs 
(NSAIDs) and oral corticosteroids (<10 mg/day); and use 
of low-potency topical corticosteroids in sensitive areas 
were permitted. Patients without ≥20% improvement 
from baseline in swollen or tender joint counts at week 
16 were switched to open-label abatacept (early escape) 
for 28 weeks. Patients designated as an early escape or 
with missing data were imputed as non-responders.
study assessments
For patients with available baseline BMI data, all analyses 
were conducted by baseline BMI subgroup: underweight/
normal (<25 kg/m2), overweight (25–30 kg/m2) and obese 
(>30 kg/m2). Patient demographics and disease charac-
teristics were also reported by BMI subgroup. Treatment 
response by BMI subgroup at week 24 was assessed by deter-
mining the proportion of patients with ACR20 response, 
Disease Activity Score in 28 joints (DAS28) (C reactive 
protein (CRP)) ≤3.6 or <2.6, and Health Assessment 
Questionnaire-Disability Index response (reduction from 
baseline ≥0.35). Structural damage was assessed by deter-
mining the rates of radiographic non-progression (defined 
as change from baseline ≤0 in PsA-modified total Sharp/
van der Heijde score).
statistical analyses
Baseline patient demographics and disease characteris-
tics were analysed descriptively according to the baseline 
BMI subgroup (percentage for categorical variables and 
mean (SD) for continuous variables). Rates for treatment 
response and radiographic non-progression in each BMI 
subgroup were determined at week 24 and compared 
between subgroups using univariable and multivariable 
analyses with the underweight/normal BMI subgroup 
as the reference. Key potential confounding factors for 
treatment efficacy were included in the multivariable 
model. Results are presented as ORs with corresponding 
95% CIs; p values were calculated for each treatment 
outcome by BMI subgroup, based on a logistic regression 
model. The ORs were statistically significant when the 
95% CIs did not cross 1. An additional stratified multi-
variable analysis was performed to evaluate treatment 
responses by baseline BMI subgroup at week 24, (i) in 
patients who received abatacept without any concomitant 
non-bDMARD (defined as not receiving any of actarit, 
apremilast, auranofin, aurothioglucose, aurotioprol, 
aurotioprol gold salt, azathioprine, bucillamine, chloram-
bucil, chloroquine, cyclosporine, gold salts, gold sodium 
thiomalate, hydroxychloroquine, leflunomide, loben-
zarit, methotrexate, mizoribine, penicillamine, sulfasala-
zine, tiopronin or tofacitinib); concomitant NSAIDs, oral 
corticosteroids or topical corticosteroids were permitted, 
and (ii) in those who received abatacept in combination 
with a non-bDMARD.
ResulTs
Analysis population
Baseline BMI data were available for 212/213 and 210/211 
patients randomised to abatacept or placebo, respectively. 
In the abatacept group, 31/212 (14.6%) patients were 
underweight/normal, 77/212 (36.3%) patients were 
overweight and 104/212 (49.1%) patients were obese. In 
the placebo group, 39/210 (18.6%) patients were under-
weight/normal, 57/210 (27.1%) were overweight and 
114/210 (54.3%) were obese. Patient demographic and 
disease characteristics at baseline by BMI subgroup are 
presented in table 1.
Treatment response by BMI—univariate analysis
In the abatacept group, there were no significant differ-
ences in the likelihood of achieving treatment outcomes 
at week 24 in the obese or overweight versus under-
weight/normal subgroup (p≥0.17 for all measurements) 
(figure 1A). In the placebo group, patients in the obese 
versus underweight/normal BMI subgroup were signifi-
cantly less likely to achieve an ACR20 response (OR 0.40; 
95% CI 0.18 to 0.90; p=0.03) or DAS28 (CRP) <2.6 (OR 
0.34; 95% CI 0.13 to 0.87; p=0.02) at week 24 (figure 1B). 
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Table 1 Baseline patient characteristics by BMI
Abatacept (n=212) Placebo (n=210)
Underweight/
normal
(n=31)
Overweight
(n=77)
Obese
(n=104)
Underweight/
normal
(n=39)
Overweight
(n=57)
Obese
(n=114)
Age, years 52.4 (11.3) 49.8 (10.5) 51.5 (10.7) 46.1 (11.8) 48.6 (10.7) 51.8 (11.0)
Female (%) 67.7 42.9 63.5 41.0 40.4 64.0
BMI 22.6 (1.7) 27.5 (1.5) 35.4 (5.5) 22.9 (1.6) 27.5 (1.4) 36.0 (5.4)
Weight, kg 61.9 (9.4) 77.6 (10.4) 97.2 (18.8) 64.0 (9.7) 79.1 (9.6) 98.0 (19.3)
Prior TNFi, n (%) 20 (64.5) 51 (66.2) 57 (54.8) 22 (53.9) 31 (54.4) 75 (65.8)
Concomitant MTX, n (%) 23 (74.2) 43 (55.8) 62 (59.6) 28 (71.8) 36 (63.2) 61 (53.5)
Concomitant oral 
corticosteroids,
n (%)
10 (32.3) 21 (27.3) 22 (21.2) 11 (28.2) 11 (19.3) 26 (22.8)
PsA duration, years 9.0 (8.0) 7.6 (7.5) 8.6 (8.7) 9.1 (8.8) 9.4 (8.7) 8.4 (8.0)
TJC(68) 18.6 (14.6) 20.1 (14.1) 22.3 (12.4) 15.8 (11.2) 17.9 (11.9) 20.9 (13.7)
SJC(66) 10.6 (8.6) 10.9 (6.4) 13.4 (8.4) 10.1 (5.5) 11.1 (7.2) 11.5 (7.6)
HAQ-DI n=30
1.3 (0.6)
1.3 (0.7) 1.3 (0.8) 1.1 (0.8) 1.2 (0.7) 1.4 (0.7)
CRP, mg/L 13.1 (23.7) n=76
14.6 (25.7)
13.9 (15.6) 19.7 (54.6) 11.1 (20.0) n=112
14.1 (21.9)
DAS28 (CRP) 4.8 (1.1) n=75
5.0 (1.1)
n=103
5.1 (1.0)
4.5 (1.2) 4.8 (0.9) n=111
5.1 (1.0)
Erosion score n=29
9.1 (16.3)
n=75
13.5 (28.9)
n=101
14.0 (31.3)
20.2 (27.8) n=55
11.8 (29.4)
n=112
8.1 (20.0)
Dactylitis, n (%) 13 (41.9) 36 (46.8) 43 (41.4) 10 (25.6) 26 (45.6) 36 (31.6)
Enthesitis* 2.1 (2.0) 1.9 (1.8) 2.2 (2.1) 1.7 (2.0) 2.1 (2.1) 1.8 (1.9)
PASI† n=23
5.6 (4.9)
n=54
6.3 (6.5)
n=69
8.7 (9.5)
n=30
5.0 (4.5)
n=43
7.0 (7.0)
n=75
8.2 (9.0)
PsA-modified total SHS n=29
16.9 (32.7)
n=75
22.4 (50.0)
n=101
25.2 (56.2)
n=34
34.6 (47.8)
n=55
22.7 (54.9)
n=112
15.2 (39.7)
BASDAI n=30
6.1 (2.0)
n=75
6.4 (2.1)
n=103
6.2 (2.1)
5.9 (2.2) n=56
6.1 (2.2)
n=113
6.3 (2.0)
Data are expressed as mean (SD) unless otherwise noted.
Underweight/normal, BMI <25 kg/m2; overweight, BMI 25–30 kg/m2; obese, BMI >30 kg/m2.
*Measured using the Leeds Enthesitis Index.
†For patients with baseline BSA ≥3%.
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BMI, body mass index; BSA, body surface area affected; CRP, C reactive 
protein; DAS28, Disease Activity Score in 28 joints; HAQ-DI, Health Assessment Questionnaire-Disability Index; MTX, methotrexate; PASI, 
Psoriasis Area and Severity Index; PsA, psoriatic arthritis; SHS, Sharp/van der Heijde score; SJC, swollen joint count; TJC, tender joint 
count; TNFi, tumour necrosis factor inhibitor.
There were no significant differences in the likelihood of 
achieving other treatment outcomes between the obese 
or overweight versus underweight/normal subgroups 
(p≥0.10).
Treatment response by BMI—multivariable analyses
In the abatacept group, there were no significant differ-
ences in the likelihood of achieving treatment outcomes 
at week 24 in the obese or overweight versus underweight/
normal BMI subgroups (figure 2). In the placebo group, 
patients in the obese versus underweight/normal BMI 
subgroup were significantly less likely to achieve DAS28 
(CRP) <2.6 (OR 0.26; 95% CI 0.08 to 0.87; p=0.03; figure 2).
In the stratified multivariable analysis of patients 
receiving abatacept without any non-bDMARD and of 
those receiving abatacept in combination with a non-bD-
MARD, there were no significant differences in the like-
lihood of achieving treatment outcomes between the 
obese or overweight versus underweight/normal BMI 
subgroups in either cohort (figure 3).
dIsCussIOn
In this post hoc analysis of the ASTRAEA study, baseline 
BMI did not impact treatment response to SC abatacept 
in patients with active PsA across a range of measures. This 
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Figure 1 Univariate model of adjusted* comparisons of treatment response at week 24 between BMI subgroups in patients 
receiving (A) abatacept and (B) placebo. An OR >1 indicates a higher likelihood of response, while an OR <1 indicates a lower 
likelihood of response. ORs are significant when 95% CIs do not overlap 1. *The model was adjusted for the following baseline 
factors: treatment, BMI, MTX use, prior TNFis, CRP, erosion, enthesitis, dactylitis, BASDAI and DAS28 (CRP). ACR20, American 
College of Rheumatology 20% improvement; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BMI, body mass 
index; CRP, C reactive protein; DAS28, Disease Activity Score in 28 joints; HAQ-DI, Health Assessment Questionnaire-Disability 
Index; MTX, methotrexate; SHS, Sharp/van der Heijde score; TNFis, tumour necrosis factor inhibitors.
lack of impact remained regardless of whether abatacept 
was administered alone or in combination with a non-bD-
MARD.
In contrast to the results reported here for abatacept, 
higher BMI negatively impacts the treatment response to 
TNFi.2 8 9 In a study of patients with psoriasis and concom-
itant PsA receiving adalimumab, a significantly lower 
Psoriasis Area and Severity Index (PASI) 50 response 
was achieved in patients with BMI ≥30 kg/m2 (obese) 
compared with those with a BMI <30 kg/m2 (non-obese; 
58% vs 79%; p=0.02).8 Similarly, a 24-month observa-
tional study of patients with active PsA receiving TNFi 
found that patients with a BMI ≥30 kg/m2 (obese) had 
a significantly higher risk of not achieving a combination 
of seven selected outcome measures versus patients with 
a BMI <30 kg/m2 (non-obese; HR 4.90; 95% CI 3.04 to 
7.87).9
The difference in the impact of BMI on response to 
abatacept versus TNF is seen in PsA has also been observed 
in RA. Previous findings from interventional trials and 
real-world studies showed that, as reported here for PsA, 
BMI does not affect retention or the response to abata-
cept in patients with RA.5 6 10–12 In contrast, obesity was 
significantly associated with reduced treatment response 
to TNFis in a meta-analysis of patients with rheumatic 
diseases, including RA and PsA, based on multiple 
outcome measures including European League Against 
Rheumatism response and a 75% reduction in the PASI 
score (PASI 75).2 Indeed, a recent systematic review and 
meta-analysis of patients with inflammatory diseases 
concluded that obesity reduced the efficacy of TNFis, but 
not of abatacept and tocilizumab.12
The reasons for the differences in the effects of obesity on 
response to different bDMARDs are unclear. While factors, 
such as half-life and volume of distribution, may partly 
explain these observations, it is also possible that the unique 
mechanism of action of abatacept might contribute to the 
lack of impact of BMI on accrued responses. Adipose tissue 
is a source of specific adipocytokines, such as TNF, macro-
phage chemoattractant protein-1, plasminogen activator 
inhibitor-1, interleukin-6, leptin and adiponectin, which 
are associated with a proinflammatory status in patients 
with obesity.13 It could be speculated that the increased 
levels of proinflammatory adipocytokines, particularly TNF, 
may affect the treatment response to TNFis,14 15 whereas 
the upstream selective modulation of T-cell co-stimulation 
by abatacept may be more independent and less affected by 
adipocytokines and, consequently, BMI.
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Figure 2 Multivariable model of adjusted* comparisons of 
treatment response at week 24 between BMI subgroups in 
patients receiving (A) abatacept and (B) placebo. An OR >1 
indicates a higher likelihood of response, while an OR <1 
indicates a lower likelihood of response. ORs are significant 
when 95% CIs do not overlap 1. *The model was adjusted 
for the following baseline factors: treatment, BMI, MTX use, 
prior TNFis, CRP, erosion, enthesitis, dactylitis, BASDAI and 
DAS28 (CRP). ACR20, American College of Rheumatology 
20% improvement; BASDAI, Bath Ankylosing Spondylitis 
Disease Activity Index; BMI, body mass index; CRP, C 
reactive protein; DAS28, Disease Activity Score in 28 joints; 
HAQ-DI, Health Assessment Questionnaire-Disability Index; 
MTX, methotrexate; SHS, Sharp/van der Heijde score; TNFis, 
tumour necrosis factor inhibitors.
Figure 3 Multivariable model of adjusted* comparisons of 
treatment response at week 24 between BMI subgroups in 
patients receiving abatacept (A) without any non-biologic 
DMARD and (B) in combination with a non-biologic DMARD. 
An OR >1 indicates a higher likelihood of response, while 
an OR <1 indicates a lower likelihood of response. ORs are 
significant when 95% CIs do not overlap 1. *The model was 
adjusted for the following baseline factors: treatment, BMI, 
MTX use, prior TNFis, CRP, erosion, enthesitis, dactylitis, 
BASDAI and DAS28 (CRP). ACR20, American College of 
Rheumatology 20% improvement; BASDAI, Bath Ankylosing 
Spondylitis Disease Activity Index; BMI, body mass index; 
CRP, C reactive protein; DAS28, Disease Activity Score in 
28 joints; DMARD, disease-modifying antirheumatic drug; 
HAQ-DI, Health Assessment Questionnaire-Disability Index; 
MTX, methotrexate; SHS, Sharp/van der Heijde score; TNFis, 
tumour necrosis factor inhibitors.
Interestingly, we found that, among patients receiving 
placebo, obesity was associated with less favourable 
outcomes for some measures in the obese versus under-
weight/normal BMI subgroups. This finding is consistent 
with previous reports showing that obesity is associated 
with a lower likelihood of achieving sustained minimal 
disease activity state in patients with PsA receiving none, 
any or combinations of non-bDMARDs, bDMARDs and 
NSAIDs.16 These findings are aligned with the recom-
mendation from the National Psoriasis Foundation for 
dietary weight reduction among patients with PsA who 
are overweight or obese based on evidence from a system-
atic review of 55 studies.17
The results reported here should be interpreted after 
considering the limitations of the current analysis. In 
addition to the inherent limitations of a post hoc anal-
ysis, this study included short-term data only—further 
research is needed to evaluate the long-term impact 
of BMI on treatment response to abatacept in patients 
with PsA. The early escape design of the ASTRAEA study 
represents an additional limitation, as the week 24 data 
for the placebo arm are from a mixed patient population 
of early escape patients who received abatacept between 
weeks 16 and 24 and non-early escape patients who 
continued to receive placebo.
In summary, the results reported here indicate that 
BMI does not appear to impact the response to abatacept 
administered at the approved dose of 125 mg SC weekly 
in patients with PsA across multiple outcome measures, 
similar to reported findings in RA.5 6 10 Given that obesity 
is common in patients with PsA and negatively impacts 
treatment response to TNFis,1 2 8 9 these data suggest that 
abatacept can be considered as an important treatment 
option for patients with PsA irrespective of BMI status.
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